RT Journal Article SR Electronic T1 Antenatal magnesium sulfate to prevent cerebral palsy JF Archives of Disease in Childhood - Fetal and Neonatal Edition JO Arch Dis Child Fetal Neonatal Ed FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health SP 225 OP 227 DO 10.1136/archdischild-2021-321817 VO 107 IS 2 A1 Keir, Amy K A1 Shepherd, Emily A1 McIntyre, Sarah A1 Rumbold, Alice A1 Groves, Charlotte A1 Crowther, Caroline A1 Callander, Emily Joy YR 2022 UL http://fn.bmj.com/content/107/2/225.abstract AB Magnesium sulfate given to women before birth at <30 weeks’ gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks’ gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.Data (de-identified only) are available upon reasonable request.